Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RVTY
RVTY logo

RVTY Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
93.971
Open
92.800
VWAP
93.15
Vol
984.07K
Mkt Cap
10.40B
Low
92.440
Amount
91.66M
EV/EBITDA(TTM)
15.04
Total Shares
111.80M
EV
12.70B
EV/OCF(TTM)
21.57
P/S(TTM)
3.80
Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
Show More

Events Timeline

(ET)
2026-04-09
08:10:00
Revvity Launches Cloud-Native BioDesign Software
select

News

Newsfilter
9.5
04-10Newsfilter
Revvity to Release Q1 2026 Financial Results
  • Earnings Release Schedule: Revvity will announce its Q1 2026 financial results before market open on May 5, 2026, reflecting the company's ongoing growth and development in the health sciences sector.
  • Conference Call Details: On the same day at 7:30 a.m. ET, CEO Prahlad Singh and CFO Max Krakowiak will host a conference call to discuss the financial results and future outlook in depth.
  • Company Background: Revvity focuses on health science solutions, achieving $2.9 billion in revenue for 2025 with approximately 11,000 employees, serving multiple sectors including pharmaceuticals and diagnostics, showcasing its strong market influence.
  • Global Customer Base: As part of the S&P 500 index, Revvity has customers in over 160 countries, demonstrating its extensive reach and impact in the global health technology market.
NASDAQ.COM
4.5
03-06NASDAQ.COM
Healthcare and Financial Sectors Underperforming
  • Healthcare Sector Decline: As of midday Friday, the healthcare sector is down 1.8%, with CRH plc and Revvity Inc showing losses of 4.3% and 4.0%, respectively, indicating overall weakness that may affect investor confidence.
  • ETF Underperformance: The Health Care Select Sector SPDR ETF is down 1.1% on the day and 1.63% year-to-date, reflecting a cautious investor sentiment towards the healthcare sector, potentially leading to capital outflows.
  • Financial Sector Weakness: The financial sector is also down 1.8%, with Blackrock Inc and Ares Management Corp declining by 7.4% and 6.6%, respectively, signaling market concerns over financial stocks that could impact overall market sentiment.
  • ETF Tracking Financial Stocks: The Financial Select Sector SPDR ETF is down 2.0% in midday trading and 8.30% year-to-date, indicating a lack of investor confidence in the financial sector, which may lead to broader market volatility.
seekingalpha
9.5
02-19seekingalpha
Bretton Fund Q4 2025 Performance Analysis
  • Quarterly Performance: The Bretton Fund achieved a return of 1.44% in Q4 2025, lagging behind the S&P 500's 2.66% gain, indicating a potential disadvantage in market competitiveness that may affect investor confidence.
  • Portfolio Adjustments: In Q4 2025, the fund exited its positions in Union Pacific (UNP) and Revvity (RVTY), suggesting a strategic shift in response to changing market conditions that could impact future earnings potential.
  • Market Comparison: The fund's performance trailing the S&P 500 reflects a need for reevaluation of its investment strategy to maintain competitiveness amid future market fluctuations.
  • Industry Dynamics: Union Pacific's presentation at Barclays' 43rd Annual Industrial Select Conference highlights ongoing interest in the company, which may influence the Bretton Fund's investment decisions moving forward.
Benzinga
9.5
02-03Benzinga
Revvity Reports Strong Q4 Earnings, Beats Expectations
  • Earnings Beat: Revvity reported Q4 2025 adjusted earnings of $1.70 per share, a 19.7% year-over-year increase, surpassing the consensus estimate of $1.55, indicating strong performance in the life sciences and diagnostics sector.
  • Sales Growth: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting robust market demand.
  • Positive Outlook: Revvity forecasts fiscal 2026 adjusted earnings between $5.35 and $5.45 per share, above the consensus of $5.32, demonstrating confidence in future growth prospects.
  • Sales Guidance: The company anticipates fiscal 2026 sales between $2.96 billion and $2.99 billion, higher than the consensus of $2.93 billion, indicating a year-over-year growth of 4%-5% and organic growth of 2%-3%.
Benzinga
6.0
02-03Benzinga
Wall Street Analysts Adjust ROKU Ratings
  • Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on ROKU stock, indicating a divergence in market sentiment regarding the company's future prospects, which could influence investor decisions and market mood.
  • Market Reaction Monitoring: While specific rating changes were not detailed, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor subsequent market developments.
  • Impact of Rating Changes: Upgrades or downgrades from analysts can lead to short-term volatility in ROKU's stock, making it essential for investors to consider these rating changes in their investment strategies.
  • Investor Recommendations: When considering the purchase of ROKU stock, investors are advised to reference the latest analyst ratings and market trends to make more informed investment decisions.
seekingalpha
9.5
02-02seekingalpha
Revvity Q4 2025 Earnings Exceed Expectations
  • Strong Financial Performance: Revvity reported $772 million in revenue for Q4 2025, reflecting a 4% year-over-year growth, with Diagnostics revenue reaching $390 million, up 10%, showcasing the company's resilience and growth potential in a challenging environment.
  • Adjusted EPS Exceeds Expectations: The company achieved an adjusted EPS of $1.70, surpassing market expectations, with a full-year adjusted EPS of $5.06, indicating effective management strategies in response to adverse policy conditions.
  • Robust Future Outlook: Management projects organic growth for 2026 to be in the range of 2% to 3%, with total expected revenue between $2.96 billion and $2.99 billion, reflecting a cautiously optimistic view on market recovery while emphasizing disciplined capital allocation.
  • Strategic Investments and Innovations: Revvity announced the acquisition of ACD/Labs software and the launch of the AI models as a service platform Signals Xynthetica, which are expected to drive future revenue growth and enhance market competitiveness through collaboration with Lilly's TuneLab.
Wall Street analysts forecast RVTY stock price to rise
10 Analyst Rating
Wall Street analysts forecast RVTY stock price to rise
6 Buy
4 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
105.00
Averages
113.38
High
123.00
Current: 0.000
sliders
Low
105.00
Averages
113.38
High
123.00
Barclays
Luke Sergott
Overweight
to
Equal Weight
downgrade
$118 -> $95
AI Analysis
2026-04-14
Reason
Barclays
Luke Sergott
Price Target
$118 -> $95
AI Analysis
2026-04-14
downgrade
Overweight
to
Equal Weight
Reason
Barclays analyst Luke Sergott downgraded Revvity to Equal Weight from Overweight with a price target of $95, down from $118. The firm sees margin risk heading into the company's Q1 report as well as potential competitive threats to flow cytometry reagents from Waters. Flow reagents are a small portion of Revvity's overall revenues, but instrumental in the company hitting its growth targets, the analyst tells investors in a research note.
Evercore ISI
Outperform
to
Outperform
downgrade
$118 -> $108
2026-04-06
Reason
Evercore ISI
Price Target
$118 -> $108
2026-04-06
downgrade
Outperform
to
Outperform
Reason
Evercore ISI lowered the firm's price target on Revvity to $108 from $118 and keeps an Outperform rating on the shares as part of the firm's medical technology and life science tools Q1 preview.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for RVTY
Unlock Now

Valuation Metrics

The current forward P/E ratio for Revvity Inc (RVTY.N) is 17.21, compared to its 5-year average forward P/E of 22.35. For a more detailed relative valuation and DCF analysis to assess Revvity Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
22.35
Current PE
17.21
Overvalued PE
25.36
Undervalued PE
19.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
17.95
Current EV/EBITDA
12.19
Overvalued EV/EBITDA
20.41
Undervalued EV/EBITDA
15.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.60
Current PS
3.19
Overvalued PS
5.27
Undervalued PS
3.92

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what stock should I buy right now
Intellectia · 377 candidates
Market Cap: >= 5.00BPrice: $10.00 - $200.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Week Rise Prob: >= 60
Ticker
Name
Market Cap$
top bottom
NTES logo
NTES
NetEase Inc
75.43B
ARCC logo
ARCC
Ares Capital Corp
13.71B
USFD logo
USFD
US Foods Holding Corp
20.63B
CPNG logo
CPNG
Coupang Inc
39.40B
QXO logo
QXO
QXO Inc
17.75B
WPM logo
WPM
Wheaton Precious Metals Corp
69.20B
stcks to trade options
Intellectia · 555 candidates
Market Cap: >= 5.00BPrice: $10.00 - $300.00Is Optionable: TrueIs Index Component: GSPC, RUT, DJI, NDXMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
NI logo
NI
NiSource Inc
22.19B
GDDY logo
GDDY
GoDaddy Inc
12.25B
HWM logo
HWM
Howmet Aerospace Inc
103.48B
SWK logo
SWK
Stanley Black & Decker Inc
14.24B
TGT logo
TGT
Target Corp
52.84B
PTCT logo
PTCT
PTC Therapeutics Inc
5.85B
find similar stocks of hims and hers
Intellectia · 208 candidates
Market Cap: 300.00M - 15.00BPs Ratio: <= 15.00Is Optionable: TrueAnnual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
GH logo
GH
Guardant Health Inc
14.98B
ICLR logo
ICLR
ICON PLC
14.12B
PEN logo
PEN
Penumbra Inc
14.03B
SOLV logo
SOLV
Solventum Corp
13.94B
SNN logo
SNN
Smith & Nephew PLC
13.91B
NBIX logo
NBIX
Neurocrine Biosciences Inc
13.50B
Best stocks with highest gains
Intellectia · 14 candidates
Market Cap Category: mid, largeRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
AMGN logo
AMGN
Amgen Inc
185.02B
VRTX logo
VRTX
Vertex Pharmaceuticals Inc
117.00B
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
51.17B
BNTX logo
BNTX
Biontech SE
29.61B
RPRX logo
RPRX
Royalty Pharma PLC
22.93B
MRNA logo
MRNA
Moderna Inc
19.46B
best Biotechnology/Health Tech gainers
Intellectia · 14 candidates
Market Cap Category: mid, largeRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
AMGN logo
AMGN
Amgen Inc
185.02B
VRTX logo
VRTX
Vertex Pharmaceuticals Inc
117.00B
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
51.17B
BNTX logo
BNTX
Biontech SE
29.61B
RPRX logo
RPRX
Royalty Pharma PLC
22.93B
MRNA logo
MRNA
Moderna Inc
19.46B
top Biotechnology/Health Tech For gainers
Intellectia · 14 candidates
Market Cap Category: mid, largeRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
AMGN logo
AMGN
Amgen Inc
185.02B
VRTX logo
VRTX
Vertex Pharmaceuticals Inc
117.00B
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
51.17B
BNTX logo
BNTX
Biontech SE
29.61B
RPRX logo
RPRX
Royalty Pharma PLC
22.93B
MRNA logo
MRNA
Moderna Inc
19.46B
GIVE ME TOP 100 LIST
Intellectia · 67 candidates
Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $0.00Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
INTC logo
INTC
Intel Corp
258.77B
MRNA logo
MRNA
Moderna Inc
19.46B
MU logo
MU
Micron Technology Inc
437.95B
GNRC logo
GNRC
Generac Holdings Inc
10.10B
ARE logo
ARE
Alexandria Real Estate Equities Inc
9.97B
KLAC logo
KLAC
KLA Corp
199.72B
en health care quien está hoy a la alza
Intellectia · 64 candidates
Price Change Pct: >= $0.00Relative Vol: >= 1.50Weekly Average Turnover: >= 1,000,000Moving Average Relationship: PriceAboveMA5
Ticker
Name
Market Cap$
top bottom
TMO logo
TMO
Thermo Fisher Scientific Inc
239.06B
AMGN logo
AMGN
Amgen Inc
185.02B
DHR logo
DHR
Danaher Corp
170.97B
MDT logo
MDT
Medtronic PLC
128.57B
VRTX logo
VRTX
Vertex Pharmaceuticals Inc
117.00B
EW logo
EW
Edwards Lifesciences Corp
49.41B

Whales Holding RVTY

E
Eversept Partners, L.P.
Holding
RVTY
+2.78%
3M Return
N
Nykredit Asset Management A/S
Holding
RVTY
-0.66%
3M Return
E
EdgePoint Investment Group Inc.
Holding
RVTY
-2.78%
3M Return
R
RGM Capital, LLC
Holding
RVTY
-15.10%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Revvity Inc (RVTY) stock price today?

The current price of RVTY is 93.03 USD — it has decreased -0.99

What is Revvity Inc (RVTY)'s business?

Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.

What is the price predicton of RVTY Stock?

Wall Street analysts forecast RVTY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVTY is113.38 USD with a low forecast of 105.00 USD and a high forecast of 123.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Revvity Inc (RVTY)'s revenue for the last quarter?

Revvity Inc revenue for the last quarter amounts to 772.06M USD, increased 5.85

What is Revvity Inc (RVTY)'s earnings per share (EPS) for the last quarter?

Revvity Inc. EPS for the last quarter amounts to 0.87 USD, increased 11.54

How many employees does Revvity Inc (RVTY). have?

Revvity Inc (RVTY) has 11000 emplpoyees as of April 21 2026.

What is Revvity Inc (RVTY) market cap?

Today RVTY has the market capitalization of 10.40B USD.